Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Erythropoietin]

B Kubanek1, I Rich, G Noé

  • 1DRK-Blutspendezentrale Ulm, Universität Ulm.

Infusionstherapie Und Transfusionsmedizin
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Recombinant human erythropoietin (rHu-EPO) can stimulate red blood cell production, but its effectiveness and cost-benefit in palliative cancer patients remain unproven. Preoperative rHu-EPO with iron shows promise in reducing transfusions for elective surgeries.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The routes of hysterectomy: A survey of current practices amongst members of the International Society for Gynaecologic Endoscopy (ISGE).

European journal of obstetrics, gynecology, and reproductive biology·2023
Same author

The influence of persistent bleeding after supracervical hysterectomy on depressive and anxious symptoms: a prospective bicenter study.

Archives of gynecology and obstetrics·2022
Same author

The influence of conventional and extended supracervical hysterectomy on sexuality and quality of life parameters: a prospective bi-center study with a special focus on postoperative spotting.

Archives of gynecology and obstetrics·2022
Same author

Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.

European journal of cancer (Oxford, England : 1990)·2016
Same author

Development of a construct-based risk assessment framework for genetic engineered crops.

Transgenic research·2016
Same author

Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.

Targeted oncology·2015
Same journal

Determination and Successful Transfusion of Anti-Gerbich-Positive Red Blood Cells in a Patient with a Strongly Reactive Anti-Gerbich Antibody.

Infusionstherapie und Transfusionsmedizin·2000
Same journal

Coexisting Anti-I/i Plus Anti Pr Cold Agglutinins in Individual Sera.

Infusionstherapie und Transfusionsmedizin·2000
Same journal

Comparison of Solvent/Detergent-Inactivated Plasma and Fresh Frozen Plasma under Routine Clinical Conditions.

Infusionstherapie und Transfusionsmedizin·2000
Same journal

Transfusion-Associated Infections with Cytomegalovirus and Other Human Herpesviruses.

Infusionstherapie und Transfusionsmedizin·2000
Same journal

Arificial Oxygen Carriers as Red Blood Cell Substitutes - Perfluorocarbons and Cell-Free Hemoglobin.

Infusionstherapie und Transfusionsmedizin·2000
Same journal

Platelet Concentrates from Automated Apheresis - Past, Present and Future Developments.

Infusionstherapie und Transfusionsmedizin·2000
See all related articles

Area of Science:

  • Hematology
  • Pharmacology

Context:

  • Recombinant human erythropoietin (rHu-EPO) stimulates red blood cell production when EPO-sensitive precursors and iron are available.
  • Iron supplementation is crucial as iron availability is a rate-limiting factor for red cell production.

Purpose:

  • To evaluate the efficacy and cost-effectiveness of rHu-EPO in treating anemia, particularly in cancer patients and for autologous preoperative transfusion programs.
  • To assess the impact of rHu-EPO on quality of life and to compare its risk-benefit ratio against homologous transfusions.

Summary:

  • rHu-EPO is effective in stimulating red blood cell production, with negligible side effects in nonrenal anemia. Antibodies against rHu-EPO are rare.
  • While rHu-EPO can increase hemoglobin, its benefit on quality of life in palliative cancer patients is not proven, raising questions about cost-effectiveness.

Related Experiment Videos

  • Preoperative rHu-EPO combined with iron supplementation significantly reduces the need for homologous transfusions in elective hip replacement surgeries.

    • Impact:

    • Further randomized trials are needed to determine the efficacy, cost-effectiveness, and risk-benefit ratio of rHu-EPO strategies compared to homologous transfusions, especially as transfusion risks have decreased.